Arthneeti
All Q1 FY26 results →
MP

Medtronic plc

Q1 FY26Health Care Equipment and Supplies

Medtronic plc Q1 FY26 Results — Earnings Call Analysis

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Price₹76
Market cap₹97.0K Cr
P/E21.7
Updated29 May 2026
Read4 min read

What the Q1 FY26 call signalled

2 of 4 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising

The short version

- Renal denervation (RDN) shows strong consumer demand with visits jumping from 50,000 in Q2 to 2.5 million in Q3; over 200 new accounts opened and 150 physicians trained. - Fiscal ’26 organic revenue growth guidance reiterated at approximately 5.5%, with Q4 expected at around 6% growth.

From Medtronic plc's Q1 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Moderate growth
  • Renal denervation (RDN) shows strong consumer demand with visits jumping from 50,000 in Q2 to 2.5 million in Q3; over 200 new accounts opened and 150 physicians trained.
  • CAS (Catheter Ablation System) revenue is expected to double, reaching $2 billion trailing by first half FY ’27 with continued high teens to strong double-digit market growth.
  • New product launches like Sphere-9 in Japan and Sphere-360 in Europe (with US trial ongoing) fuel growth in CAS.
  • Altaviva (tibial neurostimulation) and Symplicity (hypertension treatment) are early-stage but growing rapidly with direct-to-consumer marketing amplifying traction.
  • Hugo robotic surgical system just launched in the US with initial successful installations; expected to expand indications and drive growth.

2 more points from Medtronic plc's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Medtronic plc said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Medtronic is increasing R&D investment, particularly in high-growth areas like renal denervation (RDN), CAS, and robotics (Stealth AXiS and Hugo).
  • Direct-to-consumer marketing investments are being made to build referral pathways and brand awareness, e.g., for Symplicity in hypertension management.
  • The company is hiring extensively, including mappers and roles focused on market development, health economics, coding, and billing.
  • Medtronic is shifting to a more offensive capital allocation stance, combining organic investments with strategic M&A.
  • M&A focus remains on tuck-in deals and venture investments in close adjacency to existing business areas, with several opportunities prioritized.

2 more points from Medtronic plc's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Medtronic plc said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • Hugo Surgical System: Orders and installations are ramping up, with initial U.S. cases completed at Cleveland Clinic and more scheduled, indicating a growing order book.
  • Renal Denervation (Symplicity): Over 200 new account openings this quarter, reflecting strong market development and growing procedure volumes; physician participation increasing with 150+ physicians in the referral network.
  • CAS (Cardiac Ablation Systems): Trailing 12-month revenue goal target of $2 billion expected by FY '27 first half, supported by catheter portfolio strength and new product launches (Sphere-9 and Sphere-360) with ongoing trial and market expansion; strong installed base growth.

2 more points from Medtronic plc's call on order book

Create a free account to keep reading this call

Continue your research

Others in Health Care Equipment and Supplies this season

  • The Cooper Companies, Inc. (Q1 FY26)

    The Cooper Companies, Inc. Q1 FY26 quarterly results analysis. Fiscal 2026 revenue guidance is $4.3 billion to $4.35 billion, reflecting organic growth of 4.5%

Compare:vs Intuitive Surgical, Inc.vs Stryker Corporationvs Boston Scientific Corporation

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Medtronic plc and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Medtronic plc Q1 FY26 results?

- Renal denervation (RDN) shows strong consumer demand with visits jumping from 50,000 in Q2 to 2.5 million in Q3; over 200 new accounts opened and 150 physicians trained. - Fiscal ’26 organic revenue growth guidance reiterated at approximately 5.5%, with Q4 expected at around 6% growth.

What is Medtronic plc share price analysis?

Medtronic plc currently shows a below-average growth signal. The stock trades at a P/E of 21.7 with a market cap of $97,023. Investors should review the full earnings analysis for detailed insights.

Is Medtronic plc planning capital expenditure?

- Medtronic is increasing R&D investment, particularly in high-growth areas like renal denervation (RDN), CAS, and robotics (Stealth AXiS and Hugo).

Keep Medtronic plc on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.